Niagen Bioscience, Inc.
NAGE
$3.65
-$0.15-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.64M | 17.38M | 20.43M | 17.73M | 14.11M |
| Total Depreciation and Amortization | 881.00K | 785.00K | 1.45M | 1.45M | 1.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.01M | 3.63M | -950.00K | -1.96M | -2.33M |
| Change in Net Operating Assets | -16.10M | -8.30M | 484.00K | 3.99M | 6.46M |
| Cash from Operations | 4.43M | 13.50M | 21.41M | 21.21M | 19.70M |
| Capital Expenditure | -321.00K | -292.00K | -260.00K | -277.00K | -154.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 20.00K | 20.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 5.80M | -- | -- | -- | -- |
| Other Investing Activities | -494.00K | -- | -- | -- | -- |
| Cash from Investing | 4.99M | -292.00K | -260.00K | -257.00K | -134.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.00K | -12.00K | -12.00K | -12.00K | -11.00K |
| Issuance of Common Stock | 4.24M | 7.25M | 10.81M | 11.70M | 8.55M |
| Repurchase of Common Stock | -2.61M | -251.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.00K | -67.00K | -53.00K | -53.00K | -47.00K |
| Cash from Financing | 1.52M | 6.92M | 10.74M | 11.64M | 8.49M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.93M | 20.13M | 31.89M | 32.59M | 28.05M |